MA33802B1 - Dérivés d'éthynyle - Google Patents

Dérivés d'éthynyle

Info

Publication number
MA33802B1
MA33802B1 MA34890A MA34890A MA33802B1 MA 33802 B1 MA33802 B1 MA 33802B1 MA 34890 A MA34890 A MA 34890A MA 34890 A MA34890 A MA 34890A MA 33802 B1 MA33802 B1 MA 33802B1
Authority
MA
Morocco
Prior art keywords
lower alkyl
alkoxy
formula
hydroxy
optionally substituted
Prior art date
Application number
MA34890A
Other languages
Arabic (ar)
English (en)
Inventor
Luke Green
Wolfgang Guba
Georg Jaeschke
Synese Jolidon
Lothar Lindemann
Heinz Stadler
Eric Vieira
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43446449&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33802(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA33802B1 publication Critical patent/MA33802B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Cette invention concerne des dérivés d'éthynyle de formule (i) ou un sel ou sel d'addition d'acide pharmaceutiquement acceptable de ceux-ci, un mélange racémique, ou l'énantiomère et/ou l'isomère optique et/ou le stéréoisomère lui correspondant. Dans la formule (i), x est n ou c-r1 ; y est n ou c-r2 ; z est ch ou n; r4 est un substituant aromatique à 6 chaînons contenant 0, 1 ou 2 atomes d'azote, éventuellement substitué par de 1 à 3 groupes, choisis parmi un atome d'halogène, un groupe alkyle inférieur, alcoxy inférieur ou nrr'; r1 est un atome d'hydrogène, un groupe alkyle inférieur, alcoxy inférieur, hydroxy, hydroxyalkyle inférieur, cycloalkyle inférieur ou est un groupe hétérocycloalkyle éventuellement substitué par un hydroxy ou un alcoxy; r2 est un atome d'hydrogène, un groupe cn, alkyle inférieur ou hétérocycloalkyle; r et r' sont indépendamment l'un de l'autre un atome d'hydrogène ou un groupe alkyle inférieur. De manière surprenante, on a maintenant découvert que les composés de formule générale i sont des modulateurs allostériques positifs (pam) du récepteur métabotrope du glutamate de sous-type 5 (mglur5) et qu'ils sont, par conséquent, utiles pour traiter les maladies liées à ce récepteur.
MA34890A 2009-12-17 2012-05-24 Dérivés d'éthynyle MA33802B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09179719 2009-12-17
PCT/EP2010/069593 WO2011073172A1 (fr) 2009-12-17 2010-12-14 Dérivés d'éthynyle

Publications (1)

Publication Number Publication Date
MA33802B1 true MA33802B1 (fr) 2012-12-03

Family

ID=43446449

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34890A MA33802B1 (fr) 2009-12-17 2012-05-24 Dérivés d'éthynyle

Country Status (27)

Country Link
US (2) US8586581B2 (fr)
EP (1) EP2513102B1 (fr)
JP (1) JP5763094B2 (fr)
KR (1) KR101407856B1 (fr)
CN (1) CN102686589B (fr)
AR (1) AR079467A1 (fr)
AU (1) AU2010332987B2 (fr)
BR (1) BR112012014770A2 (fr)
CA (1) CA2780155A1 (fr)
CL (1) CL2012001596A1 (fr)
CO (1) CO6531478A2 (fr)
CR (1) CR20120269A (fr)
EC (1) ECSP12011977A (fr)
ES (1) ES2551582T3 (fr)
IL (1) IL219371A (fr)
MA (1) MA33802B1 (fr)
MX (1) MX2012006789A (fr)
MY (1) MY162998A (fr)
NZ (1) NZ599553A (fr)
PE (1) PE20121443A1 (fr)
PH (1) PH12012500867A1 (fr)
RU (1) RU2553461C2 (fr)
SG (1) SG181779A1 (fr)
TW (1) TWI448465B (fr)
UA (1) UA107002C2 (fr)
WO (1) WO2011073172A1 (fr)
ZA (1) ZA201204429B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3006745C (fr) * 2010-11-05 2021-03-30 Oat Agrio Co., Ltd. Ethynylphenylamidine ou l'un de ses sels, son procede de production et fongicide pour applications agricoles et horticoles
CA2829170C (fr) 2011-04-26 2019-02-26 F. Hoffmann-La Roche Ag Derives d'ethynyle comme modulateurs allosteriques positifs de mglur5
US20130123254A1 (en) 2011-09-30 2013-05-16 Barbara Biemans Pharmaceutically acceptable mglur5 positive allosteric modulators and their methods of identification
UA110862C2 (uk) * 2011-10-07 2016-02-25 Ф. Хоффманн-Ля Рош Аг Похідні етинілу як алостеричні модулятори метаботропного рецептора глутамату mglur 5
WO2014056710A1 (fr) * 2012-09-27 2014-04-17 F. Hoffmann-La Roche Ag Dérivés d'aryléthynyle
CN104603110B (zh) * 2012-10-18 2016-08-31 霍夫曼-拉罗奇有限公司 作为mGluR5受体活性的调节剂的乙炔基衍生物
CN104768554B (zh) * 2012-11-07 2018-04-17 霍夫曼-拉罗奇有限公司 三唑并化合物
JP6603334B2 (ja) 2015-06-03 2019-11-06 エフ．ホフマン−ラ ロシュ アーゲー エチニル誘導体
LT3322701T (lt) 2015-07-15 2019-07-10 F. Hoffmann-La Roche Ag Etinilo dariniai kaip metabotropinių glutamato receptorių moduliatoriai
CR20190014A (es) 2016-07-18 2019-03-04 Hoffmann La Roche Derivados etinilo

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002526408A (ja) * 1998-10-02 2002-08-20 ノバルティス アクチエンゲゼルシャフト 疼痛および不安の処置のためのｍｇｌｕｒ５アンタゴニスト
CO5271680A1 (es) * 2000-02-21 2003-04-30 Smithkline Beecham Corp Compuestos
GB0027987D0 (en) * 2000-11-16 2001-01-03 Smithkline Beecham Plc Compounds
US6910976B2 (en) 2001-06-26 2005-06-28 Stx, Llc Multi-component lacrosse stick head
GB0127430D0 (en) * 2001-11-15 2002-01-09 Smithkline Beecham Corp Compounds
GB0127433D0 (en) * 2001-11-15 2002-01-09 Smithkline Beecham Corp Compounds
TWI292318B (en) * 2003-03-10 2008-01-11 Hoffmann La Roche Imidazol-4-yl-ethynyl-pyridine derivatives
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
GB0413605D0 (en) 2004-06-17 2004-07-21 Addex Pharmaceuticals Sa Novel compounds
WO2006048771A1 (fr) 2004-11-04 2006-05-11 Addex Pharmaceuticals Sa Nouveaux derives de tetrazole utilises comme modulateurs allosteriques positifs des recepteurs de glutamate metabotropiques
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
EP2308870A3 (fr) * 2005-06-01 2011-10-19 UCB Pharma S.A. Dérivés de 2-oxo-1-pyrrolidine, leurs procédés de préparation et leurs utilisations
KR101086967B1 (ko) 2005-11-15 2011-11-29 어레이 바이오파마 인크. 과다증식성 질환의 치료를 위한 ｅｒｂｂ 유형 ｉ 수용체티로신 키나제 억제제로서의 ｎ4-페닐-퀴나졸린-4-아민유도체 및 관련 화합물
KR20090024270A (ko) 2006-06-30 2009-03-06 아스트라제네카 아베 암 치료에 유용한 피리미딘 유도체
EP1972628A1 (fr) 2007-03-21 2008-09-24 Schwarz Pharma Ag Indolizines et leurs dérivés aza analogues en tant que composés actifs du SNC
AU2008245458B2 (en) * 2007-04-30 2013-01-10 Abbvie Inc. Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme
EP2162136A4 (fr) 2007-06-03 2012-02-15 Univ Vanderbilt Dérivés benzamides modulateurs allostériques positifs récepteurs métabotropiques du glutamate 5 (mglur5) et leurs procédés de fabrication et d'utilisation
TW201116532A (en) * 2009-08-05 2011-05-16 Merz Pharma Gmbh & Co Kgaa Metabotropic glutamate receptor modulators

Also Published As

Publication number Publication date
PH12012500867A1 (en) 2014-10-14
EP2513102B1 (fr) 2015-08-19
HK1171225A1 (en) 2013-03-22
US8586581B2 (en) 2013-11-19
AU2010332987A1 (en) 2012-06-07
ECSP12011977A (es) 2012-07-31
AR079467A1 (es) 2012-01-25
BR112012014770A2 (pt) 2016-03-29
PE20121443A1 (es) 2012-10-26
KR20120095472A (ko) 2012-08-28
CN102686589A (zh) 2012-09-19
IL219371A0 (en) 2012-06-28
SG181779A1 (en) 2012-07-30
NZ599553A (en) 2014-05-30
EP2513102A1 (fr) 2012-10-24
JP2013514305A (ja) 2013-04-25
AU2010332987B2 (en) 2015-08-13
KR101407856B1 (ko) 2014-06-16
JP5763094B2 (ja) 2015-08-12
TW201144314A (en) 2011-12-16
TWI448465B (zh) 2014-08-11
MY162998A (en) 2017-07-31
CN102686589B (zh) 2014-12-10
CL2012001596A1 (es) 2013-01-04
WO2011073172A1 (fr) 2011-06-23
UA107002C2 (uk) 2014-11-10
US20110152257A1 (en) 2011-06-23
US8933094B2 (en) 2015-01-13
ES2551582T3 (es) 2015-11-20
CR20120269A (es) 2012-07-04
ZA201204429B (en) 2013-02-27
RU2553461C2 (ru) 2015-06-20
CO6531478A2 (es) 2012-09-28
RU2012128551A (ru) 2014-01-27
MX2012006789A (es) 2012-07-10
IL219371A (en) 2015-02-26
US20140073638A1 (en) 2014-03-13
CA2780155A1 (fr) 2011-06-23

Similar Documents

Publication Publication Date Title
MA33802B1 (fr) Dérivés d'éthynyle
PH12012500690A1 (en) Positive allosteric modulators (pam)
CA3000761C (fr) Derive oxa spiro, son procede de preparation, et ses applications dans des medicaments
NZ788543A (en) Dimethyltryptamine derivatives and their use in psychedelic-assisted psychotherapy
CN103848785B (zh) 一类氘代3-氰基喹啉类化合物、其药用组合物、制备方法及其用途
MA42442A (fr) Dérivés d'éthynyle comme modulateurs du récepteur métabotropique au glutamate
MA29716B1 (fr) NOUVEAUX DERIVES D'IMIDAZO[1,5-a]PYRIDINES, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT.
EA200501585A1 (ru) Производные азетидинкарбоксамида и их применение при лечении нарушений, опосредованных св1 рецепторами
MA30355B1 (fr) Derives d'azabicyclo [3. 1. 0] hexyle utilises comme modulateurs des recepteurs de la dopamine d3
AR063454A1 (es) Derivados acetamida de diazepan como inhibidores selectivos de 11 beta - hsd1. procesos de obtencion y composiciones farmaceuticas.
CA3111649A1 (fr) Composes tricycliques agissant sur des proteines crbn
MA35133B1 (fr) Dérivés d'éthynyle comme modulateurs allostériques positifs de mglur5
MA31674B1 (fr) Dérivés de 7 -alkynyl-1,8-naphthyridones, leur préparation et leur application en thérapeutique
MA38012B1 (fr) Dérivés d'éthynyle comme modulateurs de l'activité des récepteurs mglur5
WO2007039781A3 (fr) Nouveaux composes
MA38885B1 (fr) Dérivés d'éthynyle modulateurs allosteriques positifs (pam) du recepteur metabotropique du glutamate 4 (mglu4)
MX2011007272A (es) Piperidinas de aroilamino y heteroaroilamino sustituidas como inhibidores de glyt-1.
CA2450274A1 (fr) Derives de benzoxazepine et leur utilisation comme stimulants du recepteur de l'ampa
FR2854634A1 (fr) Nouveaux derives de thiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MA32019B1 (fr) Derives d'azetidines, leur preparation et leur application en therapeutique
MA37895A1 (fr) Dérivés d'aryléthynylpyrimidine substitués modulateurs allostériques du récepteur métabotrope 5 de glutamate, utiles pour le traitement, par ex. Schizophrénie, maladies cognitives, syndrome x fragile, autisme, psychose et obésité
KR20250137706A (ko) Nlrp3 억제제
JP2024544554A (ja) ピラゾロ縮合環化合物及びその使用
TW202333713A (zh) 一種噠嗪類化合物、其藥物組合物及應用
EA201000832A1 (ru) Замещённые 3-гидроксипиридины и содержащие их фармацевтические композиции